Is Crinetics Pharmaceuticals Stock a Buy?

Crinetics Pharmaceuticals (NASDAQ: CRNX) faces the ultimate biotech paradox: Its newly approved drug Palsonify could either justify the stock's $4.3 billion valuation or expose it as dangerously overpriced. The U.S. Food and Drug Administration (FDA) approval on Sept. 25 transforms this clinical-stage company into a commercial powerhouse with the first once-daily oral treatment for acromegaly.Wall Street's thinking big. The stock surged 28% on the news. But with only 11,000 diagnosed patients in America and a lofty $290,000 annual price tag, can this rare disease drug actually deliver the returns investors are banking on? Let's break down the company's commercial opportunity, key risks, and valuation to find out.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool